Influence of a half-marathon run on NT-proBNP and troponin T.
暂无分享,去创建一个
G. Lippi | M. Montagnana | F. Schena | G. Banfi | C. Tarperi | G. Salvagno | G. Guidi | M. Gelati
[1] A. Jaffe,et al. Risk stratification for heart failure and death in an acute coronary syndrome population using inflammatory cytokines and N-terminal pro-brain natriuretic peptide. , 2007, Clinical chemistry.
[2] C. Schindler,et al. Medical and economic long-term effects of B-type natriuretic peptide testing in patients with acute dyspnea. , 2007, Clinical chemistry.
[3] Claudio Passino,et al. Comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP immunoassays in chronic and acute heart failure: a systematic review. , 2007, Clinical chemistry.
[4] T. Neilan,et al. Elevation of myeloperoxidase in conjunction with cardiac-specific markers after marathon running. , 2006, American journal of clinical pathology.
[5] J. Marshall,et al. Myocardial Injury and Ventricular Dysfunction Related to Training Levels Among Nonelite Participants in the Boston Marathon , 2006, Circulation.
[6] J. Mair,et al. Utility of N-terminal pro-B-type natriuretic peptide to differentiate cardiac diseases from noncardiac diseases in young pediatric patients. , 2006, Clinical chemistry.
[7] T. Meyer,et al. Reproducibility and clinical significance of exercise-induced increases in cardiac troponins and N-terminal pro brain natriuretic peptide in endurance athletes , 2006, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.
[8] G. Lippi,et al. Influence of physical exercise and relationship with biochemical variables of NT-pro-brain natriuretic peptide and ischemia modified albumin. , 2006, Clinica chimica acta; international journal of clinical chemistry.
[9] M. Panteghini,et al. 10% CV concentration for the fourth generation Roche cardiac troponin T assay derived from Internal Quality Control data , 2006, Clinical chemistry and laboratory medicine.
[10] C. Herzog,et al. Multi-biomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death. , 2004, Clinical chemistry.
[11] David A Morrow,et al. BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. , 2004, Congestive heart failure.
[12] W. Herrmann,et al. No difference in N-terminal pro-brain natriuretic peptide (NT-proBNP) concentrations between endurance athletes with athlete’s heart and healthy untrained controls , 2004, Heart.
[13] P O Collinson,et al. Analytical performance of the N terminal pro B type natriuretic peptide (NT‐proBNP) assay on the Elecsys™ 1010 and 2010 analysers , 2004, European journal of heart failure.
[14] Wen-Sheng Huang,et al. Circulating brain natriuretic peptide values in healthy men before and after exercise. , 2002, Metabolism: clinical and experimental.
[15] D. Costill,et al. Calculation of percentage changes in volumes of blood, plasma, and red cells in dehydration. , 1974, Journal of applied physiology.